Search clinical trials for: LY03003 ( Rotigotine, extended-release microspheres)

Total 761 results

Maimonides Medical Center

Recruiting

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome (PWS-GXR)

Aggression | Behavioral Symptoms | Pathologic Processes | Nervous System Diseases | Obesity | Neurologic Manifestations | Neurobehavioral Manifestations | Congenital Abnormalities | Overnutrition | Nutrition Disorders | Genetic Diseases, Inborn | Intellectual Disability | Self-Injurious Behavior | Abnormalities, Multiple and other conditions

United States
Walter Reed National Military Medical Center

Completed

Local Anesthetics on Postsurgical Analgesia Following Posterior Colporrhaphy

Postoperative Pain

United States
Shire

Completed

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention-deficit/Hyperactivity Disorder

Spain, Belgium, United States, Netherlands, United Kingdom, Italy, Germany, Canada, France, Sweden
Jacobus Pharmaceutical

Terminated

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children

Crohn's Disease

United States
Rhode Island Hospital
National Institute on Drug Abuse (NIDA); Alkermes, Inc.

Completed

Pre-Release VIVITROL for Opioid Dependent Inmates

Substance-Related Disorders

United States
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea

Lymphorrhea

Italy
The University of Texas Health Science Center at...
Shire

Completed

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

United States
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fasted Conditions

Healthy

India
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Cedars-Sinai Medical Center
Astellas Pharma Inc

Completed

Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

End Stage Renal Disease

United States
Shire

Completed

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

Colitis, Ulcerative

United States
NYU Langone Health
Alkermes, Inc.; New York City Department of Health and Mental Hygiene

Completed

Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail

Opiate Dependence

United States
Hannover Medical School

Completed

The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)

Metabolic Syndrome

Germany
Cingulate Therapeutics

Completed

CTx-1301 Comparative Bioavailability Study

ADHD

United States
Stanford University

Completed

Effects of Epidural Lidocaine on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® After Cesarean Delivery

Epidural Analgesia, Obstetric

United States
Abbott

Completed

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

Pediatric Epilepsy

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Terminated

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Diabetic Neuropathy, Painful | Diabetic Polyneuropathy

United States
Yale University
Veloxis Pharmaceuticals

Recruiting

Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.

Kidney Transplant; Complications

United States
Yale University
University of South Florida; New York University; Icahn School of Medicine at... and other collaborators

Completed

Guanfacine in Children With Tic Disorders

Tourette Syndrome | Tourette Disorder

United States
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.

Urination Disorders
Walter Reed Army Medical Center
Abbott

Terminated

Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

Atherosclerosis

United States
Shire

Completed

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

Attention-Deficit/Hyperactivity Disorder

United States
University of Alabama at Birmingham
Heron Therapeutics

Withdrawn

Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting

Chemotherapy-induced Nausea and Vomiting

United States
Shire

Completed

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

Healthy

United States
Hospital Central Dr. Luis Ortega

Completed

Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery

Surgery

Venezuela
Supernus Pharmaceuticals, Inc.

Recruiting

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Epilepsy | Seizures, Epileptic

Australia
University of California, San Francisco
The CARESTAR Foundation

Terminated

Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder

Substance Use | Alcohol Use Disorder | Alcohol Abuse or Dependence

United States
US Department of Veterans Affairs

Completed

Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury

Spinal Cord Injury

United States
Massachusetts General Hospital
Abbott

Completed

Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

Bipolar Disorder | Mania

United States
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions

Healthy

India
Medical College of Wisconsin

Completed

Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder

Bipolar Disorder

United States
Oregon Health and Science University
National Institute on Drug Abuse (NIDA)

Completed

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

HIV | Methamphetamine Abuse

United States
Virginia Commonwealth University
Abbott

Completed

Tolerability and Efficacy of Depakote-extended Release in the Elderly

Epilepsy | Seizures | Elderly

United States
UCB Pharma

Completed

The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting

Attention Deficit Hyperactivity Disorder
University of Saskatchewan
AstraZeneca

Completed

Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

Depressive Disorder, Major
Wake Forest University
EKR Therapeutics, Inc

Terminated

Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing

Hip Arthroplasty

United States
Shaare Zedek Medical Center

Unknown

Safety and Effectiveness of Tramadex-OD After Knee Arthroscopy

Postoperative Pain

Israel
Johnson & Johnson Taiwan Ltd

Terminated

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

Schizophrenia

Taiwan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

Healthy

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Suspended

Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

Opioid-use Disorder

United States
Theresa Zesiewicz, MD

Terminated

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

Restless Leg Syndrome

United States
National Cancer Institute (NCI)

Terminated

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oral Cavity Squamous Cell Carcinoma... and other conditions

United States
Shire

Completed

Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

Attention Deficit Hyperactivity Disorder (ADHD)

Spain, Germany, Ukraine, France, Italy, Austria, Belgium, Ireland, Netherlands, Poland, Romania, Sweden, United Kingdom
Endo Pharmaceuticals

Suspended

Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

Chronic Pain | Postsurgical Pain

United States
Duke University
Alkermes, Inc.; Laura and John Arnold Foundation; FHR (Fellowship Health Resources... and other collaborators

Completed

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings (DC)

Opioid-Related Disorders

United States
Boston University

Withdrawn

Bupivacaine Liposomal Injectable Suspension, Pain and Narcotic Use After Elective Orthognathic Surgery

Orthognathic Surgery

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Hypercholesterolemia, Familial | Heterozygous Familial Hypercholesterolemia
Soleno Therapeutics, Inc.

Not yet recruiting

An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

SH2B1 Deficiency Obesity | Obesity Associated With PCSK1 Mutation (rs6232 Variant) | SIM1 Deficiency Obesity
NYU Langone Health
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

Alcohol Dependence | Alcohol Use Disorder

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA); Alkermes, Inc.

Completed

VIVITROL as a Treatment for Cocaine and Alcohol Dependence

Alcohol Dependence | Cocaine Dependence

United States

Search clinical trials for: LY03003 ( Rotigotine, extended-release microspheres)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations